Since, following eribulin treatment, these miRNAs are no longer transferred to other cells via EVs, higher levels of MDR proteins and PD-L1 could be induced in tumor recipient cells, which could become more resistant to drugs and immune system. Here, CD274 is linked to neoplasm.